In a medical breakthrough, first phase-3 dengue vaccine trial begins in India

economictimes.indiatimes.com:

DengiAll is developed by the Indian pharma company Panacea Biotec and has shown good results in initial trials. Panacea Biotec is working with the Indian Council of Medical Research (ICMR), India’s top health research body, to conduct this trial. The goal is to see how well DengiAll works compared to the current standard treatments.

The trial will involve 10,335 healthy adults and will be conducted at 19 locations across 18 states and Union territories. The ICMR is funding the trial.

Health Minister J P Nadda hailed the scitific breakthrough for India's medicine, and said that this is the first major step in India's fight against dengue.

«The start of the phase 3 clinical trial for India’s first indigenous dengue vaccine is a major step in our fight against dengue. It shows our commitment to protecting people from this widespread disease and highlights India’s strengths in vaccine research and development,» Minister Nadda said.

Currently, there is no approved antiviral treatment or licensed vaccine for dengue in India. However, several companies are working on dengue vaccines.
Recently, the Drug Controller General of India (DCGI) approved phase II clinical trials for a dengue vaccine developed by the Serum Institute of India (SII).

Globally, two dengue vaccines, Qdenga and Dengvaxia, have completed phase 3 trials and received approval from the World Health Organisation.

(With inputs from TOI)